n-acetylcytidine profile

N-acetylcytidine (AcC) is a naturally occurring nucleoside found in RNA and DNA. It is formed by the acetylation of cytidine, a common nucleoside found in nucleic acids. AcC is thought to play a role in gene expression and DNA repair. It has been shown to inhibit the activity of some enzymes, including DNA polymerase. AcC has also been studied for its potential anticancer properties. Its synthesis involves the acetylation of cytidine using acetic anhydride. AcC is studied to understand its role in gene expression, DNA repair, and its potential as an anticancer agent.'

N(4)-acetylcytidine : Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	107461
CHEBI ID	70989
SCHEMBL ID	453447
MeSH ID	M0068878

Synonym
cytidine, n-acetyl-
n4-acetylcytidine
n4-acetylcytidine, >=98%
4-acetyl-1-(beta-d-ribofuranosyl)cytosine
3768-18-1
acetamide, n-(1,2-dihydro-2-oxo-1-beta-d-ribofuranosyl-4-pyrimidinyl)
n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide
acetylcytidine
n-acetylcytidine
n-[1-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-pyrimidin-4-yl]acetamide;n4-acetylcytidine
A823825
c11h15n3o6
einecs 223-195-6
n(4)-acetylcytidine
n-{1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide
CHEBI:70989
AKOS015896940
SCHEMBL453447
NIDVTARKFBZMOT-PEBGCTIMSA-N
4-n-acetyl-cytidine
n4 -acetylcytidine
n-(1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide
n-4-acetylcytidine
AC-32170
mfcd00006540
n-{1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide
n-acetyl-cytidine
4-acetyl-1-(beta-delta-ribofuranosyl)cytosine
C22293
F12709
n4-acetylcytidine;n-acetylcytidine
CS-0030784
Q20890503
AS-12329
4-acetylcytidine; n4-acetylcytidine
DTXSID40958718
4-[(1-hydroxyethylidene)amino]-1-pentofuranosylpyrimidin-2(1h)-one
HY-W019670
n4-acetyl-d-cytidine
BP-58622

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
cytidines
acetamides	Compounds with the general formula RNHC(=O)CH3.
secondary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (6.00)	18.7374
1990's	1 (2.00)	18.2507
2000's	2 (4.00)	29.6817
2010's	12 (24.00)	24.3611
2020's	32 (64.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (5.88%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	48 (94.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	3.94	2	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.6	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
caffeine [no description available]	3.94	2	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
thymidine [no description available]	2.41	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.67	3	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
cytidine [no description available]	8.39	37	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pseudouridine [no description available]	3.55	2	pseudouridines	fundamental metabolite
mannose mannopyranose : The pyranose form of mannose.	2.11	1	D-aldohexose; D-mannose; mannopyranose	metabolite
1-methyladenosine [no description available]	1.99	1	methyladenosine	human metabolite
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.87	3	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
1-methylinosine 1-methylinosine : Inosine carrying a methyl substituent at position 1 on the hypoxanthine ring.	1.99	1	inosines	metabolite
5-methylcytidine [no description available]	3.41	1	methylcytidine
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	3.76	2	methyladenosine
5-formylcytidine 5-formylcytidine: found at the first position of the anticodon of methionine tRNA from bovine liver mitochondria; structure given in first source	2.21	1
2'-o-methylcytidine [no description available]	2.21	1	methylcytidine
puromycin [no description available]	1.95	1	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
n-acetylmethionine N-acetylmethionine: RN given refers to L-isomer. N-acetylmethionine : A methionine derivative that is methionine in which one of the amine hydrogens is substituted by an acetyl group.	2.11	1	L-methionine derivative; N-acetyl-L-amino acid; N-acetylmethionine	nutraceutical
anticodon Anticodon: The sequential set of three nucleotides in TRANSFER RNA that interacts with its complement in MESSENGER RNA, the CODON, during translation in the ribosome.	2.9	4
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.04	1	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.44	2	guanosines; purines D-ribonucleoside	fundamental metabolite
hypoxanthine [no description available]	2.11	1	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
inosine [no description available]	3.55	2	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2'-o-methylguanosine 2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.	2.21	1	methylguanosine	metabolite
7-methylguanosine 7-methylguanosine : A positively charged methylguanosine in which a single methyl substituent is located at position 7.	1.99	1	methylguanosine; organic cation	metabolite
8-methylguanosine 8-methylguanosine: structure in first source	2.21	1

Condition	Relationship Strength	Studies
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
FMR1-Related Primary Ovarian Insufficiency [description not available]	2.6	1
Primary Ovarian Insufficiency Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.	2.6	1
Bladder Cancer [description not available]	2.9	2
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.9	2
Cancer of Pancreas [description not available]	4	8
Carcinoma, Ductal, Pancreatic [description not available]	2.9	2
Invasiveness, Neoplasm [description not available]	2.41	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	4	8
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.9	2
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.41	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.41	1
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.6	1
Cancer of Esophagus [description not available]	2.6	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.6	1
Anoxemia [description not available]	2.6	1
Cancer of Stomach [description not available]	2.6	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.6	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.6	1
Degenerative Diseases, Central Nervous System [description not available]	2.6	1
Acute Confusional Senile Dementia [description not available]	2.6	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.6	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.6	1
Carcinoma, Squamous Cell of Head and Neck [description not available]	3.3	3
Carcinoma, Epidermoid [description not available]	2.6	1
Cancer of Head [description not available]	3.3	3
Cancer of Mouth [description not available]	2.6	1
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	3.3	3
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.6	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	3.3	3
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.6	1
Cancer of Cervix [description not available]	2.6	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.6	1
Lung Adenocarcinoma [description not available]	2.6	1
Cancer of Lung [description not available]	2.6	1
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.6	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.6	1
Lymph Node Metastasis [description not available]	2.6	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.6	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.6	1
Cancer of Larynx [description not available]	2.6	1
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.6	1
Cornea Injuries [description not available]	2.31	1
Corneal Endothelial Cell Damage [description not available]	2.31	1
Corneal Injuries Damage or trauma inflicted to the CORNEA by external means.	2.31	1
Innate Inflammatory Response [description not available]	5.2	5
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	5.2	5
Cystic Fibrosis of Pancreas [description not available]	2.11	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.11	1
Blood Pressure, High [description not available]	5.01	4
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	5.01	4
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	5.01	4
Rheumatoid Arthritis [description not available]	1.99	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	1.99	1

n-acetylcytidine

Description

Cross-References

Synonyms (40)

Roles (1)

Drug Classes (3)

Bioassays (1)

Research

Studies (50)

Market Indicators

Research Demand Index: 11.77

Study Types